Castleman Disease patients who do not respond to the only drug currently approved by the FDA may have another option that targets a specific pathway called PI3K/Akt/mTOR.
Castleman Disease patients who do not respond to the only drug currently approved by the FDA may have another option that targets a specific pathway called PI3K/Akt/mTOR.